key: cord-0325500-o4sefq8w
authors: Lin, D.; Zeng, D.; Gu, Y.; Fleming, T.; Krause, P.
title: Reliably Assessing Duration of Protection for COVID-19 Vaccines
date: 2021-12-27
journal: nan
DOI: 10.1101/2021.12.22.21268201
sha: 63d677f38ac6a0225217d4f75e929bf29bede798
doc_id: 325500
cord_uid: o4sefq8w

Decision-making about booster dosing for COVID-19 vaccine recipients hinges on reliable methods for evaluating the longevity of vaccine protection. We show that modeling of protection as a piecewise linear function of time since vaccination for the log hazard ratio of the vaccine effect provides more reliable estimates of vaccine effectiveness at the end of an observation period and also more reliably detects plateaus in protective effectiveness as compared with the traditional method of estimating a constant vaccine effect over each time period. This approach will be useful for analyzing data pertaining to COVID-19 vaccines and other vaccines where rapid and reliable understanding of vaccine effectiveness over time is desired.

1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The recent surge of COVID-19 cases has heightened the debate on vaccine boosters, but any decision to give additional doses to those who have been fully vaccinated should be based on careful assessments of the benefits and risks for both individuals and society. 1 A major consideration in this decision is the durability of vaccine protection against COVID-19 disease, particularly against severe disease. Although evidence on waning vaccine efficacy or effectiveness (VE) is emerging from phase 3 clinical trials and observational studies, 2−8 more reliable insights could enable properly informed decision-making about the need for and the optimal timing of booster shots. Here, we discuss the sensitivity of existing analyses to waning VE and show how changes in disease risks over calendar time can influence that sensitivity. We then propose an approach with greater sensitivity that can properly adjust for other influencing factors, such as emerging viral variants. Improved assessments of real-world vaccine effectiveness using this approach could also have major implications for decisionmaking regarding other products.

Waning protection is commonly assessed by comparing VE estimates over successive time periods. 3,5−8 The VE estimates are obtained under the standard Cox or Poisson model assuming a constant VE over each time period and thus will be referred to as VE Const hereafter. In the presence of waning, VE Const represents an average of the time-varying vaccine effect over the time period, weighted by when the events occur, and thus tends to be higher than the true VE at the end of the time period, especially when the time period is long. In addition, VE Const tends to be less precise when each time period is short, such that larger studies are required to draw firm conclusions.

To obtain more precise and up-to-date estimates of protection, we advocate fitting a Cox model with two time indexes: the event times are measured from the start of the study in calendar time, and the log hazard ratio for the vaccine effect is a continuous, piecewise-linear function of time elapsed since vaccination. 9−10 The corresponding VE on the hazard rate (VE HR ) represents exponential deterioration of vaccine effect by time since vaccination. 10−11

Because it measures the vaccine effect on the instantaneous risk of disease at the current time, rather than an overall benefit over a broad time period, VE HR is more sensitive than VE Const to the level of waning. In addition, measuring time to disease occurrence from trial 2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.22.21268201 doi: medRxiv preprint initiation allows us to account for waxing and waning infection rates and compare disease incidence between the vaccinated and unvaccinated groups at the same calendar time. 9−10,12

To illustrate the relative sensitivity of these approaches, we simulated a clinical trial mimicking the enrollment pattern of the BNT162b2 study 3 and the trend of COVID-19 infections occurring in the United States during that trial. We assumed that the true VE HR of a hypothetical vaccine decreases (linearly in the log hazard ratio) from a peak of 95% at full vaccination (i.e., 7 days after dose 2) that lasts one month to 70% at 6 months after full vaccination. 9−10 The means of VE Const over 1000 replicates are 94.4%, 89.9%, and 81.6% over 0-2, 2-4, and 4-6 months, respectively, which under-represent the degree of waning at the end of each time period (Fig. 1A) . The under-estimation by VE Const of the true level of waning was accentuated, even when estimation is performed within two-month intervals, because vaccinations tended to coincide with an early peak in the incidence of infections and then this incidence rate waned for many months thereafter. This resulted in a high percentage of exposures occurring during the earlier part of each two-month interval when the true VE was higher. We simulated a second trial by shifting the enrollment period to 6 months later, such that the period with the strongest vaccine effects coincided with a nadir in exposure rates. Then the means of VE Const over 1000 replicates are 94.7%, 89.5%, and 78.8% over 0-2, 2-4, and 4-6 months, respectively (Fig. 1B) . VE Const , in essence providing estimates of VE at the mid-points of these 2-month intervals, does not have the same level of overestimation of VE in the second trial relative to the first. In both trials, the estimated VE HR curve is close to the truth ( Fig. 1A and 1B) .

Neutralizing antibodies conferring short-term protection could wane log-linearly, leading to waning of VE over several months yet, for a lengthy duration thereafter, VE could be maintained at a plateau due to cell-mediated or memory immune responses that remain nearly constant over time. Thus, we simulated two more trials by letting the true VE reach a plateau at 5 months post full vaccination in the first trial and at 3.5 months in the second. In the first trial, 6-month VE is somewhat overestimated by VE Const and somewhat underestimated by VE HR (Fig. 1C) . In the second trial, both VE Const and VE HR provide estimates of 6-month VE that are close to the truth (Fig. 1D) . Importantly, the information 3 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.22.21268201 doi: medRxiv preprint allow high risk cohorts to be vaccinated first). It is important to recognize that additional factors not easily addressed through modeling (e.g., having a declining number of "controls" over calendar time who remain truly unvaccinated, given an increasing percentage having had infections or vaccinations obtained outside of primary healthcare systems) could be influential. Therefore, changes in underlying immunization rates, disease incidence among vaccinees and controls and follow-up rates among vaccinees and controls over relevant time periods should also be reported. 8 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.22.21268201 doi: medRxiv preprint

Considerations in boosting COVID vaccine immune responses

Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence

Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant -National Healthcare Safety Network

Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among Adults -United States

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. The Lancet

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintThe copyright holder for this this version posted December 27, 2021. ; https://doi.org/10.1101/2021.12.22.21268201 doi: medRxiv preprint